Keywords
How to Cite
Abstract
The article is devoted to the characteristics of vascular lesions in patients with type 2 diabetes mellitus, which constitute a group at very high cardiovascular risk, and to pharmacotherapeutic methods of their correction. According to modern views, the authors consider in detail the pathogenetic mechanisms of vessel wall damage, which contribute to a rapid progression of atherosclerosis and development of cardiovascular events in this group of patients. Particular
attention is paid to the role of oxidative stress, atherogenic dyslipidemia, and endothelial dysfunction; the necessity for a multifactorial pathogenic therapy in the prevention and treatment of vascular complications in type 2 diabetes mellitus, is grounded. The authors expound systematically the characteristics of alpha-lipoic acid effects on the metabolic processes in the body, its role in the antioxidant protection system, and its cytoprotective properties. According to
evidence-based medicine, detailed patterns of alpha-lipoic acid use are given; the rationale of its use in combination therapy is demonstrated, in order to reduce residual cardiovascular risk in patients with diabetes mellitus.
References
2. Maritim A.C., Sanders R.A. et al. Diabetes, oxidative stress, and antioxidants // J. Biochem. Molec. Toxicol. 2003, 17, 24-38.
3. Golbidi S., Badran M., Laher I. Diabetes and alpha lipoic acid // Front. Pharmacol. 2011, 2, 69.
4. Poh Z.X., Goh K.P. A current update on the use of alpha lipoic acid in the management of type 2 diabetes mellitus // Endocr. Metab. Immune Disorders - Drug Targets. 2009, 9, 392-398.
5. Лупинская З.А., Зарифьян А.Г., Гурович Т.Ц, Шлейфер С.Г. Эндотелий. Функция и дисфункция. Бишкек: КРСУ, 2008. 373 c.
6. Мохорт Т.В. Альфа-липоевая кислота: полифакторное влияние и обоснование возможностей использования при сахарном диабете // Медицинские новости. 2011, № 3, 67-71.
7. Harding S.V., Rideout T.C., Jones P.J. Evidence for using alpha-lipoic acid in reducing lipoprotein and inflammatory related atherosclerotic risk // J. Diet. Suppl. 2012, 9, Suppl. 2, 116-127.
8. Yi X., Xu L., Hiller S. et al. Reduced alpha-lipoic acid synthase gene expression exacerbates atherosclerosis in diabetic apolipoprotein E-deficient mice // Atherosclerosis. 2012, 223, Suppl.1, 137-143.
9. Hamilton S.J., Chew G.T., Watts G.F. Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus // Diab. Vasc. Dis. Res. 2007, 4, 89-102.
10. Kim H.S., Kim H.J., Park K.G. et al. Alpha-lipoic acid inhibits matrix metalloproteinase-9 expression by inhibiting NF-kappaB transcriptional activity // Exp. Molec.
Med. 2007, 39, 106-113.
11. Lee H.A., Hughes D.A. Alpha-lipoic acid modulates NFkappaB activity in human monocytic cells by direct interaction with DNA // Exper. Gerontol. 2002, 37, Suppl. 2-3, 401-410.
12. Ying Z., Kampfrath T., Sun Q. et al. Evidence that α-lipoic acid inhibits NFκ-B activation independent of its antioxidant function // Inflammation Res. 2011, 60, 219-225.
13. Oliveira A.M. de, Rondó P.H., Luzia L.A. et al. The effects of lipoic acid and a-tocopherol supplementation on the lipid profile and insulin sensitivity of patients with type 2 diabetes mellitus: a randomized, doubleblind, placebo-controlled trial // Diab. Res. Clin. Practice. 2011, 92, 253-260.
14. Rahman S.T., Merchant N., Haque T. et al. The impact of lipoic acid on endothelial function and proteinuria in quinapril-treated diabetic patients with stage I hypertension: results from the QUALITY study // J. Cardiovasc. Pharmacol. Therap. 2012, 17, Suppl. 2, 139-145.
15. Xiang G., Pu J., Yue L. et al. Alpha-lipoic acid can improve endothelial dysfunction in subjects with impaired fasting glucose // Metabolism. 2011, 60, Suppl. 4, 480-485.